Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33328344.
- Also identified by DOI 10.1158/1078-0432.CCR-20-3914.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Using transcriptional profiling, three robust subtypes of nonsquamous non-small cell lung cancer were defined, independently of initiating oncogenic driver events. Subtype-specific differential sensitivity to MEK1/2 inhibitors was reported and an interaction between the mucinous subtype, <i>STK11/LKB1</i> genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified.<i>See related article by Daemen et al., p. 1162</i>.
Medical subject headings
- Adenocarcinoma of Lung
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms